ISTANBUL escrs

Augmented adjunctive Mitomycin-C in combined phacotrabeculectomy

Session Details

Session Title: Special Cases
Session Date/Time: Friday 20/02/2015 | 08:30-10:30
Paper Time: 08:36
Venue: Sadirvan B
First Author: : A.Saeed EGYPT
Co Author(s): :    T. AboulNasr              

Abstract Details

Purpose:

To provide a favorable long-term IOP control in patients with primary open angle glaucoma(1ry OAG) with coexistent cataract , by evaluating the efficacy and safety of the additional beneficial effects of the early postoperative topical Mitomycin-C (MMC) drops in addition to intraoperative MMC application in comparison to the effect of combined phacotrabeculectomy with only intraoperative adjunctive MMC.

Setting:

Ophthalmology department, Benha University Hospital, Egypt.

Methods:

Controlled randomized prospective clinical trial included 52 eyes of 45 patients diagnosed with 1ry OAG with coexistent cataract. They were divided into two equal groups: the ‘augmented adjunctive MMC phacotrabeculectomy with postoperative MMC drops (0.03mg/ml)’ treatment group A and the ‘phacotrabeculectomy with only adjunctive MMC’ as a control group B. The patients were evaluated up to 24 months postoperatively to get the cumulative probability of surgical success , documentation of IOP, number of IOP-lowering drugs, best corrected visual acuity (BCVA), perimetry, adverse effects, complications, and any additional surgical intervention.

Results:

Group A achieved a cumulative probability of complete success of 0.76 and qualified success of 0.92 at the end of the 24months study period, while group B achieved 0.44 and 0.84 respectively. Group A also achieved statistically significant lower mean IOP values than group B with statistically significant less antiglaucoma drugs at all postoperative visits. (p<0.05) BCVA and VF parameters showed similar mean values when comparing both groups. There were no statistically significant differences when comparing the complications and additional interventions between both groups. No significant adverse effects were caused by topical MMC augmentation.

Conclusions:

Augmented adjunctive MMC could present an efficient, safe, familiar and applicable treatment modality for a successful combined phacotrabeculectomy. Postoperative MMC topical eye drops can provide a favorable long-term IOP outcome representing a simple novel way to successful combined glaucoma and cataract surgery.

Financial Disclosure:

NONE

Back to previous